{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T06:07:15Z","timestamp":1773641235892,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,2,18]],"date-time":"2010-02-18T00:00:00Z","timestamp":1266451200000},"content-version":"vor","delay-in-days":1447,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Addict"],"published-print":{"date-parts":[[2006,3,4]]},"abstract":"<jats:p>This retrospective study of patients treated in a ninety\u2010day, inpatient, dual\u2010diagnosis treatment program examined antipsychotic effectiveness in this population using length of stay in treatment and successful program completion as outcome measures. All patients with co\u2010occurring substance dependence and schizophrenia or schizoaffective disorder treated with olanzapine, risperidone, ziprasidone, and typical depot neuroleptics from January 2001 to December 2003 (<jats:italic>n<\/jats:italic> = 55) are the subjects of this study. Patients stayed longer in treatment when taking risperidone (82 \u00b1 19 days) or ziprasidone (74 \u00b1 21 days) compared with olanzapine (44 \u00b1 30 days) or typicals (47 \u00b1 36 days). Eighty\u2010eight percent of risperidone patients and 64% of ziprasidone patients successfully completed the program, while only 33% of olanzapine patients and 40% of patients on typicals successfully completed the program. Risperidone and ziprasidone were associated with significantly better program performance than olanzapine or depot typicals in this population. Possible reasons for this difference are discussed.<\/jats:p>","DOI":"10.1080\/10550490500528613","type":"journal-article","created":{"date-parts":[[2006,4,4]],"date-time":"2006-04-04T20:33:17Z","timestamp":1144182797000},"page":"166-173","source":"Crossref","is-referenced-by-count":25,"title":["Differing Effects of Antipsychotic Medications on Substance Abuse Treatment Patients with Co\u2010occurring Psychotic and Substance Abuse Disorders"],"prefix":"10.1111","volume":"15","author":[{"given":"Elizabeth B.","family":"Stuyt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terrie A.","family":"Sajbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,2,18]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1300\/J251v02n01_02"},{"key":"e_1_2_5_3_2","volume-title":"Drug Abuse Treatment: A National Study of Effectiveness","author":"Hubbard RL","year":"1989"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1037\/0893-164X.11.4.261"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03450190043026"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.52.4.469"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1176\/ps.47.8.853"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.143.8.993"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.1997.tb00565.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(97)00144-0"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1037\/1064-1297.8.1.97"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0740-5472(97)00134-7"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033464"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200002000-00016"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/105504901750227831"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/070674370104600919"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/070674379704200420"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0740-5472(01)00205-7"},{"issue":"19","key":"e_1_2_5_19_2","first-page":"47","article-title":"Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting","volume":"60","author":"Noordsy DL","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.52.4.501"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2002.02229.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.15.2305"},{"key":"e_1_2_5_23_2","volume-title":"Changing for Good","author":"Prochaska JO","year":"1986"},{"key":"e_1_2_5_24_2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"e_1_2_5_25_2","volume-title":"Stat View(r) 5 Reference","author":"SAS Institute Inc","year":"1998"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.6.553"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.6.1018"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.3.249"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200115060-00005"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200205000-00008"},{"key":"e_1_2_5_31_2","first-page":"344","article-title":"Effects of clozapine on smoking in chronic schizophrenic outpatients","volume":"56","author":"George TP","year":"1995","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.adt.0000129084.99647.20"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/070674370204700710"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00009-7"}],"container-title":["The American Journal on Addictions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1080%2F10550490500528613","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1080\/10550490500528613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T14:36:19Z","timestamp":1698762979000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1080\/10550490500528613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,4]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,3,4]]}},"alternative-id":["10.1080\/10550490500528613"],"URL":"https:\/\/doi.org\/10.1080\/10550490500528613","archive":["Portico"],"relation":{},"ISSN":["1055-0496","1521-0391"],"issn-type":[{"value":"1055-0496","type":"print"},{"value":"1521-0391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,4]]}}}